Commercial Risk Committee Adviser — Medical Technology Incentives

The mandate

A medical-technology commercial risk committee is reconsidering incentive structures that reward shipment growth without sufficiently testing the behaviour they encourage. Discount ladders, sales targets and distributor awards interact with collection, inventory and product-service obligations. The adviser will provide an independent finance perspective on those interactions, helping the committee decide whether the economics and evidence controls support the intended commercial outcome.

The engagement runs for twelve months from 26 October 2026. Four days each month are reserved for review of incentive proposals, a behavioural scenario paper and working discussion; the monthly committee session is included in the retainer. Responses to bounded ad-hoc questions are due within two business days. Travel or additional meetings beyond the agreed allocation require advance scope approval and cannot quietly expand the commitment.

This appointment carries no line authority and no executive responsibility. It is not a director appointment, compliance officer function or delegated approval seat. Internal compliance and legal teams retain interpretation of applicable requirements, while sales leadership owns execution. The adviser will challenge the financial assumptions and evidence architecture, including whether apparently successful incentives create stock loading, deferred claims or unrecognised obligations that emerge after the measurement period.

At term end the committee chair may recommend renewal to the board. Continuation depends on board approval of a separate written term capped at twelve months and a fresh agreement about channel-review capacity and remuneration. Other non-competing engagements are possible within the reserved capacity, but work for distributors negotiating the same schemes or competing device suppliers must be disclosed before appointment. Transaction-linked remuneration and payments from channel counterparties are incompatible. Advisory access is limited to approved information, with recusal where a disclosed financial interest could impair independent challenge.

What you will own

• Challenge incentive proposals against plausible distributor and sales behaviour, asking whether the reward encourages genuine demand, accelerated ordering, reduced collection discipline or commitments that become expensive after the target period.
• Shape a financial exposure assessment that distinguishes the immediate scheme budget from contingent rebates, future service burdens and settlement uncertainty, helping the committee compare designs on a consistent basis.
• Test the evidence requirements for award eligibility, questioning whether shipment, activation or collection records can verify the intended outcome without relying solely on statements from the rewarded party.
• Advise on scenario-based guardrails that internal owners could incorporate into approval papers, preserving commercial discretion while making material exceptions and residual financial risk visible to the committee.
• Review post-launch economic outcomes for contradictions between reported target achievement and realised contribution, recommending questions for management rather than instructing employees to change customer or distributor arrangements.
• Press the committee to distinguish financial challenge from clinical and compliance judgement, identifying the specialist conclusions needed when an incentive could alter service obligations or sensitive channel conduct.

Candidate qualifications

• Bring 22–28 years in finance with director-level or regional experience in medical technology, healthcare products or a comparably complex channel business. Show an incentive programme whose economics you challenged before or after launch. Your evidence should identify the behavioural issue and financial consequence, rather than equating a smaller budget with a better commercial design.
• Demonstrate analytical judgement across commercial planning, accruals and internal controls. You must explain how eligibility evidence, target thresholds and settlement timing can alter a scheme's financial risk. A recognised finance qualification or equivalent technical grounding is expected; the adviser must also recognise when compliance, legal or clinical expertise is required and avoid presenting financial reasoning as a substitute for it.
• Have influenced executive or committee discussions through specific, balanced challenge. The selection conversation will test your ability to examine the assumptions of a successful sales team without becoming either adversarial or deferential. Experience interpreting imperfect channel data and distinguishing genuine demand from timing effects is more relevant than an extensive history of attending governance meetings.
• Be able to protect four monthly preparation days and the included committee session, while responding within the agreed two-business-day window. Disclose supplier, distributor and competing-sector work together with related financial interests. Independence requires refusing counterparties' reward-linked payments and being willing to recuse from a particular discussion when transparency alone cannot adequately control an actual conflict.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 13 October 2026. Mandate reference CVU-ADV-2026-IND-102.